PENTOXIFYLLINE for endometriosis
Per Open Targets, pentoxifylline is a Phase 3 clinical candidate for endometriosis acting as an adenosine A2b receptor antagonist.
Hypothesized mechanism
Pentoxifylline may attenuate the inflammatory processes of endometriosis through antagonism of the adenosine A2b receptor.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 3 of 10 overall, a exploratory reading, from a pathway rated exploratory in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Only a single Open Targets database entry is provided, describing one mechanism of action (adenosine A2b receptor antagonism). No independent mechanistic lines converge; there is just one source and one claim.
Rigor
The evidence is a curated database annotation indicating PHASE_3 clinical candidacy for endometriosis, which implies human-relevant context, but no actual study models, data, or outcomes are presented. The claim is a descriptive target/MOA mapping rather than experimental evidence.
Specificity
The claim specifies a defined molecular target (adenosine A2b receptor antagonist), giving moderate specificity of action. However, pentoxifylline is a non-selective phosphodiesterase inhibitor with broad effects, so the single annotated target understates its pharmacology and limits confidence in specificity.
Plausibility
Adenosine A2b receptor signaling has links to inflammation, and endometriosis is an inflammatory condition, providing a plausible target-phenotype connection. However, the claim does not articulate how this target modulates the disease, so the fit is only weakly supported.
Consistency
With only one claim there is no internal conflict, but also no multiple signals to confirm directional agreement. The single annotation is consistent with the proposed use but cannot establish convergence.
Independent reading, reported beside the score
One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.
MATRIX cross-reference Top 1%
Every Cure’smachine-learned treatment-probability model, drawn from a biomedical knowledge graph across roughly 1,800 drugs and 22,000 diseases. It provides a model-based estimate of how plausible a drug-disease link is given the structure of biomedical knowledge, reported alongside the substrate’s own evidence.
For this pair. MATRIX places this pair at Top 1%, with a treat-score of 3.65 (higher is better; across the pairs we cover, scores span about 3.1 to 4.5).
Scored over MATRIX’s own entities, confirming the same drug and disease: CHEBI:7986 (drug) and MONDO:0005133 (disease). Validate against the source: Every Cure’s MATRIX dataset ↗.
More on the MATRIX cross-reference and its provenance →Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), PENTOXIFYLLINE (a Small molecule) is a clinical candidate for endometriosis (maximum clinical stage PHASE_3); its mechanism of action is Adenosine A2 receptor antagonist on target adenosine A2b receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →